StreetInsider.com News Articles

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 19 Jun 2026 07:00:00 -0400

FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15, 2026, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 172 employees covering an aggregate of 204,925 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 19 Jun 2026 07:00:00 -0400

The RSUs will vest

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 19 Jun 2026 07:00:00 -0400

The RSUs will vest

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 19 Jun 2026 07:00:00 -0400

The RSUs will vest

Form 4 CASTLE BIOSCIENCES INC For: Jun 16 Filed by: Oelschlager Kristen M

Thu, 18 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260618/26666349.html

Form 4 CASTLE BIOSCIENCES INC For: Jun 16 Filed by: Oelschlager Kristen M

Thu, 18 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260618/26666349.html

Form 4 CASTLE BIOSCIENCES INC For: Jun 15 Filed by: MAETZOLD DEREK J

Wed, 17 Jun 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260617/26661090.html

Form 4 CASTLE BIOSCIENCES INC For: Jun 15 Filed by: MAETZOLD DEREK J

Wed, 17 Jun 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260617/26661090.html

Form 144 CASTLE BIOSCIENCES INC Filed by: Oelschlager Kristen M

Tue, 16 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260616/26654637.html

Form 144 CASTLE BIOSCIENCES INC Filed by: Oelschlager Kristen M

Tue, 16 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260616/26654637.html

CASTLE Biosciences' Barrett's esophagus test reaches 100,000 orders

Tue, 16 Jun 2026 07:03:46 -0400

Castle Biosciences, Inc. (NASDAQ: CSTL) announced that its TissueCypher Barrett's Esophagus Test has surpassed 100,000 clinical test orders, according to a company press release dated June 16, 2026.

TissueCypher is an AI-derived test designed to predict a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma. The test is indicated for patients with non-dysplastic Barrett's esophagus, indefinite for dysplasia, or with low-grade dysplasia.

Emmanuel Gorospe, M.D., medical director at Castle Biosciences, said the test "provides clinically validated risk stratification for patients with BE by identifying those at increased risk of progression to high-grade dysplasia or EAC," and

Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

Tue, 16 Jun 2026 07:00:00 -0400

FRIENDSWOOD, Texas, June 16, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its TissueCypher^® Barrett's Esophagus Test has surpassed 100,000 clinical test orders. TissueCypher is an AI-derived precision medicine test designed to predict a patient's five-year risk of progression from Barrett's esophagus (BE) to high-grade dysplasia or esophageal adenocarcinoma.

"Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a gastrointestinal cancer associated with poor survival outcomes," said Emmanuel Gorospe, M.D., MPH, FACG, FASGE, board-certified gastroenterologist and

Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

Tue, 16 Jun 2026 07:00:00 -0400

Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

Tue, 16 Jun 2026 07:00:00 -0400

Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

Tue, 16 Jun 2026 07:00:00 -0400

Form 4 CASTLE BIOSCIENCES INC For: Jun 01 Filed by: MAETZOLD DEREK J

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599053.html

Form 4 CASTLE BIOSCIENCES INC For: Jun 01 Filed by: MAETZOLD DEREK J

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599053.html

Form 144 CASTLE BIOSCIENCES INC Filed by: MAETZOLD DEREK J

Mon, 01 Jun 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260601/26585289.html

Form 144 CASTLE BIOSCIENCES INC Filed by: MAETZOLD DEREK J

Mon, 01 Jun 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260601/26585289.html

Form 4 CASTLE BIOSCIENCES INC For: May 28 Filed by: Olson Tiffany

Mon, 01 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260601/26584662.html

Form 4 CASTLE BIOSCIENCES INC For: May 28 Filed by: Olson Tiffany

Mon, 01 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260601/26584662.html

Form 4 CASTLE BIOSCIENCES INC For: May 28 Filed by: Harrison Miles

Mon, 01 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260601/26584645.html

Form 4 CASTLE BIOSCIENCES INC For: May 28 Filed by: Harrison Miles

Mon, 01 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260601/26584645.html

Form 4 CASTLE BIOSCIENCES INC For: May 28 Filed by: Goldberg Ellen

Mon, 01 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260601/26584654.html

Form 4 CASTLE BIOSCIENCES INC For: May 28 Filed by: Goldberg Ellen

Mon, 01 Jun 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260601/26584654.html